Despite some well-known variation between CLL patients, both p52 and Bcl-XL were inhibited at 0.25 μM CW15337 whereas p-p65 was unaffected, indicating specific inhibition of the non-canonical NF-κB pathway. This evidence concerns the gene BCL2L1 and B-cell chronic lymphocytic leukemia.